

第223回 Bone Biology Seminar

第43回グローバルCOE講演会共催
歯と骨の分子疾患科学の国際教育研究拠点
ーデント・メドミクスのインテリジェンスハブー


演 題:『 Drug Development for Osteoporosis 』

日 時:平成23年6月20日(月) 10:00~

場 所:MDタワー24階 共用セミナー室1

講演者:Dr. Arthur C. Santora II

Senior Director Scientific Staff Clinical Research, Endocrine
Merck Research Laboratories, Merck & Co., Inc. Rahway, NJ, USA



[Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.](#)

Barrett-Connor E, Swern AS, Hustad CM, Bone HG, Liberman UA, Papapoulos S, Wang H, de Papp A, [Santora AC](#). Osteoporos Int. 2011

[Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.](#)

Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, DaSilva C, Petrovic R, [Santora AC](#), Ince BA, Lombardi A. J Bone Miner Res. 2011; 26(2):242-51.

[Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.](#)

Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, [Santora AC](#), Ince BA. J Bone Miner Res. 2010; 25(5):937-47.

問合せ先:分子薬理学分野 野田政樹 Tel:03-5803-4061